Researchers at McGill University in Montreal have developed and tested a workflow that turns a child’s genetic diagnosis into the starting point for a personalized RNA therapy, publishing the framework this month in The American Journal of Human Genetics.
For families of children living with rare conditions, a diagnosis may finally account for their child’s symptoms, yet it frequently comes with little in the way of available treatments. McGill’s team, working with CHU Sainte-Justine, wants to make that diagnosis the beginning of a therapeutic one instead.
As the study demonstrates, the framework presents a process to bridge the gap between genetic diagnosis and the screening of individualized therapies — a path most children with rare disorders have never had.
The lead author is Julia Macintosh, a Ph.D. student in McGill’s Department of Neurology and Neurosurgery. Carl Ernst of McGill’s Department of Psychiatry, who leads the Interventional Genetics Unit at the Neuro, served as the senior author.
“This approach leverages a diagnosis to guide the design of a genetic-based therapy, with the aim of providing a more direct path to treatment,” said Julia Macintosh, lead author of the study.
Published recipe lets doctors grow patient brain cells and test custom genetic medicine
- Doctors can now follow a published, step-by-step recipe: take a blood sample, grow the patient’s own brain cells in a dish, and test a custom-designed genetic medicine on them.
- The therapy tested was not given to the child — it worked in laboratory cells only, so no child has been treated under this framework yet.
- The point is access: by making the process repeatable, the researchers hope children beyond a few specialized centers can benefit.
How the pipeline runs from blood draw to brain cells
The process begins with a patient’s blood sample, which is used to create stem cells carrying the same genetic mutation as the child. Those stem cells are then turned into neurons in the laboratory, giving researchers a living model of how the mutation affects that specific patient’s brain cells.
Onto those cells the team applies antisense oligonucleotides, or ASOs — a type of genetic medicine that can be designed to change how a gene is processed.
As a demonstration, the team ran the workflow on a young patient with Kleefstra syndrome, an uncommon genetic condition associated with developmental delays, intellectual disability, and trouble with speech and communication. Using the child’s own cells, they designed and tested ASOs aimed at the specific genetic change involved. Testing of the therapy took place solely in laboratory cells, and studies in humans will need to follow before any clinical application.
Why diagnosis has been a dead end for so many families
Many rare disorders affect only a handful of patients worldwide, which makes the economics of drug development brutal: no pharmaceutical company can recoup the cost of a therapy for a condition with a dozen patients. As a result, opportunities to pursue personalized treatments have depended in part on access to specialized expertise, research programs, and resources — a form of geographic and institutional luck that McGill’s team wants to remove.
The emerging field is called interventional genetics, and its premise is simple to state: use the genetic diagnosis not only to explain disease but to design the treatment. What this study adds is a single, documented workflow connecting diagnosis to therapy screening, rather than the ad hoc, one-off efforts that have characterized the field to date.
“This is a wonderful example of researchers at McGill University and CHU Sainte-Justine working together to support families in Quebec. We hope this model can also be useful to genetic diagnostic centers around the world,” said Carl Ernst, senior author of the study.
What the framework changes for health systems
McGill’s report frames the goal explicitly: expand access to treatments for neurodevelopmental disorders to more families in Quebec and elsewhere, by linking a precision genetic medicines pipeline to an already well-established genetic diagnostics team. The paper, titled “Integrating clinical diagnostics with interventional genetics for neurodevelopmental disorders,” is positioned as a roadmap other diagnostic centers can copy.
| Stage | What happens | Status in this study |
|---|---|---|
| Genetic diagnosis | Blood sample identifies the child’s mutation | Completed |
| Cell model | Stem cells converted into patient-matched neurons | Completed |
| Therapy design | ASOs built against the specific genetic change | Completed for one Kleefstra syndrome case |
| Laboratory testing | ASOs tested on patient-derived cells | Completed |
| Human testing | Clinical trials in children | Not begun; further research required |
On funding, McGill’s announcement states the study was supported in part by D2R, alongside the university and CHU Sainte-Justine. The published paper lists 26 authors including Julia Macintosh, Khadijé Jizi, and Ying Zhang.
No personalized ASO therapy approved for clinical use from this framework
No personalized ASO therapy from this framework has been approved for clinical use, so there is nothing for families to request or administer yet.
Where the field goes from here
The technologies needed to develop personalized genetic therapies already exist, the authors note in the study. The challenge now is integrating them into health care systems so more patients can benefit.
“A major goal of this work is to expand access to treatments for neurodevelopmental disorders to more families in Quebec and elsewhere,” said Carl Ernst.
References
- Macintosh, J., Jizi, K., Zhang, Y., et al. “Integrating clinical diagnostics with interventional genetics for neurodevelopmental disorders.” The American Journal of Human Genetics (2026). The American Journal of Human Genetics
- McGill University: “New approach aims to make personalized RNA therapies accessible to more children with rare genetic brain disorders” (October 23, 2026). mcgill.ca
- Medical Xpress: “New approach aims to make treatment more accessible for children with rare brain disorders.”
Consult a qualified physician regarding any diagnosis or treatment.
- Debunked: Unpublished, Halted Study Falsely Claims Vaccines Cause Chronic Conditions in Children
- Men’s Health Guide Details Upper-Lower Workout Split Template
- What the FTC's Personalized-Pricing Orders Ask Delta, Uber and Walmart (daybreakwire.com)
- Researchers Develop Genetic Test Predicting Glaucoma Risk Decades Early (time.news)